Johnson & Johnson (JNJ) said Sunday that results from a phase 2 trial of its experimental combination of Talvey and Tecvayli showed a nearly 79% overall response rate with durability in patients with a certain type of cancer.
The results cover patients with triple-class exposed relapsed or refractory multiple myeloma who have true extramedullary disease.
The company said that 54% of the patients achieved a complete response or better in the study. Results from responders indicated "deep and durable" responses, the company said.
Treatment with the combination led to 61% of patients progression free and alive at one year, Johnson & Johnson said.
Extramedullary disease represents an aggressive form of multiple myeloma.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。